TOP TIERMARKET NEWSWIRE
News & sentiment

SUMMIT THERAPEUTICS (SMMT) — News & AI sentiment

SUMMIT THERAPEUTICS (SMMT) news roundup. 8 stories in the past week, 60 over 30 days. Average 30-day sentiment is 61.3/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
8
avg sentiment 58.8/100
30d stories
60
avg sentiment 61.3/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

SMMT news in the last 24 hours, 7 days, 30 days and 90 days

How much SMMT coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowSMMT storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days858.8/100SMMT headlines →
Last 30 days6061.3/100SMMT headlines →
Last 90 days11560.6/100SMMT headlines →

Latest stories on SMMT

Summit Therapeutics stock rating reaffirmed at Citizens on trial data
Investing.com Analyst Ratings56 · neutralanalyst
1d ago
Jefferies reiterates Buy on Summit Therapeutics stock, $30 target
Investing.com Analyst Ratings63 · neutralanalyst
2d ago
2d ago
3d ago
4d ago
5d ago
5d ago
5d ago
Oct 21
Oct 21
Oct 21
Oct 21
Oct 19
Oct 19
Oct 19
Oct 19
Oct 16
Bernstein reiterates Summit Therapeutics stock rating on trial concerns
Investing.com Analyst Ratings38 · neutralanalyst
Oct 5
Oct 5
Oct 5
Oct 2
Oct 2
Oct 2
Oct 2
Oct 2
Open SMMT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →